Aurobindo Pharma's CuraTeQ Biologics Gets ANVISA Approval for Hyderabad Facility
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has received Good Manufacturing Practice (GMP) approval from Brazil's health regulator ANVISA for its biosimilars manufacturing facility in Hyderabad. The approval followed an inspection covering biological APIs, sterile products, and related manufacturing and quality control operations for four biosimilar products. CuraTeQ's facility is also certified by the European Medicines Agency and the World Health Organization. This approval enhances the company's ability to supply biosimilars to Brazil and the wider Latin American market.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (56/100). Lens Score 44/100.
Outlets measured: businessstandard, thehindu. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–58/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thehindu broke this story on 21 Jul, 01:28 pm. Other outlets followed.